PCSANot HalalF
Unlock full report, free

Is Processa Pharmaceuticals (PCSA) Stock Halal?

Compliance Status

Not Halal

Screened on Nov 14, 2026 · AAOIFI Standard 21

F

Non-Compliant

0Score

Is Processa Pharmaceuticals, Inc. (PCSA) halal? Not Halal. Based on AAOIFI screening, Processa Pharmaceuticals, Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

Quote this verdict

HalalScreener rates Processa Pharmaceuticals, Inc. (PCSA) Not Halal, 0/100, grade F under AAOIFI Standard 21, screened Nov 14, 2026. Source: https://halalscreener.app/en/stock/PCSA

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

0.0% of 30.0% limit
PRO DETAIL

The verdict above is final and free.

Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.

Card needed, nothing charged today

Screened according to AAOIFI Standard 21

What this means for you

Most scholars advise not holding PCSA

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

Share this verdict

A receipt-style image with the math on it, so whoever you send it to can check it.

Processa Pharmaceuticals, Inc.

PCSA

Processa Pharmaceuticals, Inc.

NASDAQHealthcareUS

$1.82

Market Cap: 5.1M

Get an email if PCSA's halal status changes

We re-screen Processa Pharmaceuticals, Inc. daily. If the verdict moves, you hear about it the same day.

Free. One click sets it up, and you can unsubscribe any time.

About Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The company's leading investigational drug, PCS499, is an oral tablet presently undergoing Phase 2B clinical assessment. It aims to treat both ulcerative and non-ulcerative manifestations of necrobiosis lipoidica, a chronic and disfiguring dermatological condition. Processa's portfolio also features PCS12852, a unique selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. This compound is currently in Phase 2A clinical trials for its potential application in managing gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia. Furthermore, the firm is advancing PCS3117, a cytosine analog, which has reached Phase 2B clinical trials for its use in pancreatic cancer and non-small cell lung cancer. Another candidate, PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase, is progressing through Phase 1B clinical trials for metastatic colorectal and breast cancers. In addition, Processa is developing PCS11T, an analog derived from the drugs SN38 and irinotecan, intended for the treatment of diverse cancer types. The company was founded in 2011 and maintains its corporate headquarters in Hanover, Maryland.

Sector: Healthcare · Industry: Biotechnology

Why this does not pass

  • Interest-bearing deposits are over the 30% limit.

Screened under AAOIFI Standard 21. The exact figure behind this is part of Pro; the failing check and its limit are always free.

Shariah Compliance Status

AAOIFI Standard 21Updated Nov 14, 2026
AI Compliance InsightProSee plans
Revenue BreakdownProSee plans

Compliance History

  1. Not Halalnow

    since Nov 2026

  2. Under Review

    until the change above

  3. Not Halal

    until the change above

Tracked since Aug 2026. Updates automatically on each re-screen.

Fiscal: Q3 2026Data source: EDGAR
Free · No credit card required

Know the day PCSA's verdict changes

A free account keeps watch on 3 stocks and emails you when a verdict moves. You also get 3 questions for the AI Scholar. No card needed.

8,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Processa Pharmaceuticals, Inc. (PCSA) halal to invest in?
Processa Pharmaceuticals, Inc. (PCSA) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.
Why did Processa Pharmaceuticals, Inc. get a F compliance rating?
Processa Pharmaceuticals, Inc. (PCSA) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 0.0% (limit 30%); interest-bearing deposits over the 30% limit; prohibited income well clear of the 5% limit. The grade reflects the margin of safety across all three ratios relative to their thresholds.
What could change Processa Pharmaceuticals, Inc.'s Shariah verdict?
Processa Pharmaceuticals, Inc.'s verdict is recalculated at every re-screen, including the one that follows each new quarterly or annual report. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.
How often is Processa Pharmaceuticals, Inc. re-screened for Shariah compliance?
Processa Pharmaceuticals, Inc. (PCSA) is screened from the latest financial statements on record, currently those for fiscal Q3 2026. The 500 largest US-listed companies, and every stock on a HalalScreener watchlist or portfolio, are re-screened daily against the current market cap; every other stock at least once a week. When the company files a new quarterly or annual report with the SEC, it is re-screened from that filing: we check the SEC's filing feed every 15 minutes and the earnings calendar every day. Last screened: Nov 14, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.